Clinical Trials on Renal Impairments

Total 12647 results

UCB Pharma
Parexel

Completed

Pharmacokinetic (PK) Study in Japanese Non-epileptic Renal Impaired Patients

Healthy Subjects | Renal Impairments

Japan
Yuhan Corporation

Completed

A Study to Evaluate the Pharmacokinetics and Safety of YHD1119 in Subjects With Renal Impairment and Healthy Subjects

Healthy Volunteer | Renal Impairments

Korea, Republic of
Eisai Inc.

Completed

Phase 0 Study in Healthy, Hepatic and Renal Impaired Subjects to Obtain Plasma for Lenvatinib Protein Binding

Hepatic Impairment; Renal Impairment

United States
JW Pharmaceutical

Completed

A Safety, PK, PD and Food Effect Study of URC102 in Healthy Adults and Patients With Renal Impairment

Healthy, Renal Impairment

Korea, Republic of
Kowa Research Institute, Inc.

Completed

Safety, Tolerability, and Pharmacokinetic of Single Dose of Pitavastatin 4 mg in Severe Renal Patients Versus Healthy Adult Volunteers

Severe Renal Impairment

United States
Gilead Sciences

Terminated

A Phase 1 Study to Assess the Effect of Severe Renal Impairment on the Pharmacokinetics, as Well as Safety/Tolerability, of Ranolazine

Severe Renal Impairment

United States
Centre for Probe Development and Commercialization
St. Joseph's Healthcare Hamilton; McMaster University

Completed

A Single Centre Open Label Comparison of [I-123]-Ortho-Iodohippuric Acid (OIH) With [Tc-99m]-Mercaptoacetyltriglycine (MAG3) for Assessment of Renal Tubular Function

Renal Function Impairment

Canada
Sichuan Haisco Pharmaceutical Group Co., Ltd
The First Affiliated Hospital of Zhengzhou University

Completed

Safety and Pharmacokinetics/Pharmacodynamics of HSK3486 in Patients With Impairment Renal Functions

Chronic Renal Impairment

China
Idorsia Pharmaceuticals Ltd.

Completed

A Study to Evaluate ACT-132577 in Healthy Subjects and in People With Severe Kidney Disease

Healthy Subjects | Severe Renal Impairment

Czechia
Melbourne Health

Withdrawn

Frusemide Infusion for the Prevention of Deterioration in Renal Function Post Cardiac Surgery.

Renal Impairment After Cardiac Surgery

Australia
Novartis Pharmaceuticals

Completed

Pharmacokinetics of LCZ696 in Subjects With Mild and Moderate Renal Impairment Compared to Healthy Subjects With Normal Renal Function

Mild and Moderate Renal Impairment

Russian Federation, Germany, Serbia
AstraZeneca

Completed

A Study to Assess Zibotentan Pharmacokinetics in Participants With Moderate Hepatic and Moderate Renal Impairment

Renal Impairment | Hepatic Impairment

Bulgaria
Allecra

Completed

Pharmacokinetics of Cefepime and AAI101 in Subjects With Renal Insufficiency and Healthy Subjects

PK in Patients With Various Degrees of Renal Impairment

Czechia, Hungary
Novartis Pharmaceuticals

Completed

An Open-label, Parallel-group Study to Determine the Pharmacokinetics of a Single Dose of AFQ056 in Subjects With Renal Impairment Compared to Healthy Subjects

Mild Moderate | or Severe Renal Impairment

Germany
Centre Hospitalier Universitaire de Saint Etienne
GlaxoSmithKline

Completed

Prospective, Multicentre, Open-label Study Evaluating 1.5 mg/Day of Fondaparinux. (PROPICE)

Major Orthopaedic Surgery and Renal Impairment

France
Vasopharm GmbH
Winicker Norimed GmbH

Completed

Effects of the NO-synthase Inhibitor VAS203 on Renal Function in Healthy Volunteers

Renal Function Impairment in Healthy Volunteers

Germany
Jiangsu Simcere Pharmaceutical Co., Ltd.

Not yet recruiting

Hepatic Impairment and Renal Impairment Study of SIM0417 Combined With Ritonavir

Renal Impairment | Hepatic Impairment

China
Takeda

Completed

Phase I Open-label Study to Evaluate Pharmacokinetics of TAK-272 in Participants With Renal or Hepatic Impairment

Renal Impairment | Hepatic Impairment

Japan
Bracco Diagnostics, Inc

Terminated

Renal Safety of Iopamidol Versus Iodixanol During Coronary Angiography in Diabetic Patients (RECARE)

Diabetes Mellitus | Chronic Renal Impairment

United States
Daiichi Sankyo Co., Ltd.

Completed

Study of CS-3150 in Combination With ARB or ACE Inhibitor in Hypertensive Patients With Moderate Renal Impairment

Hypertension With Moderate Renal Impairment

Japan
VIVUS LLC

Completed

To Compare the Pharmacokinetics of Avanafil in Subjects With Mild and Moderate Renal Impairment to Subjects With Normal Renal Function.

Renal
H. Lundbeck A/S

Terminated

Pharmacokinetics of Lu AF35700 in Subjects With Renal Impairment

Renal Failure

Germany
AbbVie
Roche-Genentech

Completed

Study to Assess Adverse Events and the Movement of Oral Venetoclax Tablet Through the Body of Female Participants Aged 18-75 Years With Impaired Renal Function

Renal Impairment | Renal Disease

United States
Merck Sharp & Dohme LLC

Completed

A Study of MK-0616 in Participants With Moderate Renal Impairment (MK-0616-007)

Moderate Renal Impairment

United States
Bausch Health Americas, Inc.

Completed

Pharmacokinetics, Safety, and Tolerability of Methylnaltrexone (MNTX) in Subjects With Impaired Renal Function

Renal Impairment

United States
Mitsubishi Tanabe Pharma America Inc.

Completed

PK Study in Subjects With Renal Impairment (Severe and if Required Mild & Moderate) Compared to Subjects With Normal Renal Function

Renal Impairment | Normal Renal Function

Germany
Novartis Pharmaceuticals

Completed

Pharmacokinetics Study of Asciminib in Subjects With Impaired Renal Function Compared to Matched Healthy Volunteers

Renal Impairment

Germany, Bulgaria
Genfit

Completed

Nitazoxanide Pharmacokinetic Parameters in Renal Impaired Subjects

Renal Impairment | Kidney Disease | Renal Disease

United States
Exelixis

Completed

A Single-Dose Study to Assess the Pharmacokinetics of Cabozantinib (XL184) Capsules in Subjects With Impaired Renal Function

Healthy | Renal Impairment

United States
Shanghai Vinnerna Biosciences Co., Ltd.
Sponsor GmbH

Completed

A Study in Subjects With Renal Impairment Compared to Subjects With Normal Renal Function

Healthy Subjects | Subjects With Renal Impairment

China
Janssen Research & Development, LLC

Recruiting

A Study to Evaluate the Effect of Renal Impairment on JNJ-42847922 in Adult Participants

Renal Impairment

United States
Merck Sharp & Dohme LLC

Completed

A Study to Evaluate Molnupiravir (MK-4482; MOV) in Participants With Severe Renal Impairment (MK-4482-003)

Renal Impairment

United States
Sanofi

Completed

Study to Assess the Plasma Concentration of Tolebrutinib Given as a Tablet to Adult Participants With Renal Impairment Compared to Healthy Participants

Renal Impairment

United States, Germany
F2G Biotech GmbH

Completed

A Phase I Study to Assess the Pharmacokinetics of Olorofim in Subjects With Renal Impairment

Renal Impairment

United States
BioVersys AG
CRU Hungary Kft; CRU Hungary Early Phase Unit

Completed

Pharmacokinetics and Safety of BV100 Administered as Single Intravenous Infusion to Subjects With Renal Impairment

Renal Impairment

Hungary
Haisco Pharmaceutical Group Co., Ltd.

Completed

A Study to Evaluate the Pharmacokinetics of HSK7653 in Subjects With Renal Impairment

Renal Impairment

China
Merck Sharp & Dohme LLC

Terminated

Study of a Single Intravenous (IV) Dose of MK-3402 in Participants With Impaired Renal Function and in Healthy Controls (MK-3402-004)

Renal Impairment

United States
Hutchison Medipharma Limited

Completed

Surufatinib Renal Impairment Study

Renal Impairment

United States
Arthrosi Therapeutics
Iqvia Pty Ltd

Completed

Pharmacokinetic Study of AR882 in Subjects With Various Degrees of Renal Impairment

Renal Impairment

United States, New Zealand
Galera Therapeutics, Inc.

Completed

Study to Evaluate the Effects of Renal Impairment on the Pharmacokinetics, Safety and Tolerability of GC4419

Renal Impairment

United States
Novartis Pharmaceuticals

Completed

Study of PK/PD, Safety and Tolerability of LIK066 in Patients With Decreased Renal Function.

Renal Impairment

United States
Novartis Pharmaceuticals

Completed

Pharmacokinetics of Dabrafenib in Subjects With Renal Impairment

Renal Impairment

United States
Novartis Pharmaceuticals

Completed

Pharmacokinetics, Safety and Tolerability of AGO178C in Subjects With Renal Deficiencies Compared With Healthy Subjects

Renal Impairment

United States
Novartis Pharmaceuticals

Completed

A Single-dose, Open-label, Parallel-group Study to Assess the Pharmacokinetics of BAF312 in Subjects With Renal Impairment Compared to Subjects With Normal Renal Function

Renal Impairment

United States, Romania
Idorsia Pharmaceuticals Ltd.

Completed

A Study to Evaluate ID-085 in People With Mild, Moderate, and Severe Kidney Disease

Renal Impairment

Germany
Akcea Therapeutics
Ionis Pharmaceuticals, Inc.

Completed

Study of ISIS 681257 in Patients With Renal Impairment Compared to Healthy Patients

Renal Impairment

United States, Canada
Merck Sharp & Dohme LLC

Completed

Pharmacokinetics (PK) and Safety of a Single Intravenous (IV) Dose of MK-3866 in Participants With Impaired Renal Function and in Healthy Controls (MK-3866-005)

Renal Impairment

United States
The Medicines Company

Completed

A Study of Inclisiran in Participants With Renal Impairment Compared to Participants With Normal Renal Function (ORION-7)

Renal Impairment

New Zealand
Wockhardt
Clinartis

Completed

To Investigate The Pharmacokinetics Of Intravenous WCK 5222 (FEP-ZID) In Patients With Renal Impairment

Renal Impairment

United States
Hoffmann-La Roche

Completed

A Study to Investigate the Effect of Renal Function and Hemodialysis on the Pharmacokinetics (PK) of RO7079901

Renal Impairment

United States

3

Subscribe